BNET Industries

Telik Inc.

(TELK) is in the Pharma Industry

Market Cap:$44.8M
Last Fiscal Year Sales:$2.9M
  • Public
  • US
Dow Jones Description

Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small cell lung cancer. A second development candidate, TELINTRA (TLK199), is in a Phase 2 clinical trial in myelodysplastic syndrome and may also have utility in the treatment of additional blood disorders characterized by low levels of blood cells. We developed our product candidates through the use of our proprietary TRAP technology, which enables the rapid and efficient discovery of small molecule drug candidates. In addition to our internal drug development programs, we partner with select academic institutions and pharmaceutical and biotechnology companies to apply TRAP to new drug development programs for a range of diseases. We intend to commercialize our cancer products in North America, and to partner with multinational pharmaceutical companies to assist in the commercialization of our cancer products in other territories.

President, CEO and Chairman
Michael Wick
Number of Employees 50
Contact Information

3165 Porter Ave

Palo Alto, California 94304

www.telik.com

(650) 845-7700

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Telik Announces Third Quarter 2009 Financial Results

    11/14/09 - Financial Announcement - View Story

News & Analysis

telik inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Mary Ann Gray President, Gray Strategic Advisors, Llc
Cynthia Butitta Chief Operating Officer and Chief Financial Officer
Gail L. Brown Senior Vice President and Chief Medical Officer
Steven R. Goldring Chief Scientific Officer, Research Administration, Hospital for Special Surgery
Marc Steuer Senior Vice President, Business Development
Paul M Mendelman Senior Vice President, Clinical Development
Derek Freyberg Vice President, Intellectual Property
James G. Keck Vice President, Biology Research
William P. Kaplan Vice President, General Counsel and Corporate Secretary
Carol D. DeGuzman Senior Director, Corporate Communications
Jeffrey Cleland Senior Director of Product Development
Stefan Ryser Director and Senior Vice President, Corporate Strategy
Patricia P Frias
Richard B. Newman Director

Board of Directors

Name (plus bio) Position
Michael Wick President, CEO and Chairman
Edward W. Cantrall Member of the Board of Directors
Herwig von Morze Board of Directors

Organization Position Status
Telik, Inc. President, CEO and Chairman Current
CV Therapeutics Inc. Senior Vice President of Research and Development Former
Lederle Laboratories Executive Director of Oncology Former
Harvard University Ph.D. Degree In Chemistry Former
Harvard Medical School M.D. Degree Former

Organization Position Status
Telik, Inc. President, Gray Strategic Advisors, Llc Current
Gray Strategic Advisors, LLC President Current
Raymond James Ltd. Senior Vice President Current
Informed Investors, Inc. Senior Vice President at Raymond James Current
Acadia, Inc Chairman Current
GTC Biotherapeutics, Inc. Director Current
Dyax Corp. Board of Directors Current
Hereditary Angioedema Board of Directors Current
Telik, Inc. Director Current
ACADIA Pharmaceuticals Inc. Director Current
Hereditary Angioedema Founder and President, Gray Strategic Advisors, Llc Former
Biologic Company President Former
Kidder, Peabody & Co. Vice President Former
Gray Strategic Advisors, LLC Founder Former
Kidder, Peabody & Co. Sell, Side Biotechnology Analyst Former
NeoRx Corporation Senior Scientist Former
Dillon Read Senior Biotechnology Analyst Former
Raymond James & Associates, Inc. Senior Biotechnology Analyst Former
Biologic Company Analyst Former
Raymond James Financial, Inc. Former
Schering-Plough Corporation Former
Warburg Dillon Read Former
National Cancer Institute Former
Battelle Memorial Institute Former
University of Vermont Ph.D. In Pharmacology Former
University of South Carolina BS In Biology Former

Organization Position Status
Telik, Inc. Chief Operating Officer and Chief Financial Officer Current
Connetics Corporation Chief Financial Officer Former
Finance Company Limited Vice President Former
Connetics Corporation Vice President for Finance and Administration Former
University of Wisconsin M.B.A. In Finance Former
Edgewood College B.S. In Business Former

Organization Position Status
Telik, Inc. Senior Vice President and Chief Medical Officer Current
Oncology Inc Faculty Former
Harvard Medical School Faculty Former
Department of Medicine Faculty Former
University of Rochester School of Medicine & Dentistry M.D. Degree Former
St. Mary's College M.B.A. Degree In Finance Former

Organization Position Status
Telik, Inc. Chief Scientific Officer, Research Administration, Hospital for Special Surgery Current
The Bone Associate Editor Current
Arthritis Research Associate Editor Current
Abbott Scholar Award Board of Directors Current
Telik, Inc. Member of the Board of Directors Current
Beth Israel Deaconess Medical Center Chief Former
Harvard Medical School Professor of Medicine Former
Beth Israel Deaconess Medical Center Professor Former
Peter Bent Brigham Hospital Former
Massachusetts General Hospital Former
Washington University School of Medicine M.D. Degree Former
Washington University School of Medicine Degree Former

Organization Position Status
Telik, Inc. Senior Vice President, Business Development Current
Pharmacyclics, Inc. Senior Vice President, Business Development Former
Syntex Corporation Former
SciClone Pharmaceuticals, Inc. Former
New York University M.B.A. Former
Columbia University M.S. In Electrical Engineering Former

Organization Position Status
Telik, Inc. Senior Vice President, Clinical Development Current
MedImmune, Inc. Vice President Former
University of Washington Associate Professor Former
MedImmune, Inc. Group Leader Former
University of Washington School of Medicine Associate Professor Former
Flumist Former
The Ohio State University M.D. Former
The Ohio State University B.S. Former

Organization Position Status
Telik, Inc. Vice President, Intellectual Property Current

Organization Position Status
Telik, Inc. Vice President, Biology Research Current
University of Southern California Ph.D. degree Former
North Carolina State University M.S. degree Former

Organization Position Status
Telik, Inc. Vice President, General Counsel and Corporate Secretary Current
Iprint Technologies, Inc Vice President and General Counsel Former
School of Law J.D. Degree Former
University of California, Davis J.D Former
University of California, Santa Barbara B.A. Degree In Mathematics Former
University of California B.A. Degree In Mathematics Former

Organization Position Status
Telik, Inc. Senior Director, Corporate Communications Current

Array

Organization Position Status
Telik, Inc. Senior Director of Product Development Current

In August 2008, Dr. Ryser joined Telik as Senior Vice President, Corporate Strategy. Prior to joining Telik, Dr. Ryser most recently served as founding and managing partner of Bear Stearns Health Innoventures, a $212 million private equity fund established in 2000. He also founded and managed, beginning in 1998, International Biomedicine Management Partners, a biotechnology venture fund. Previously, Dr. Ryser held various senior management positions of increasing responsibility at F. Hoffmann-La Roche, including Scientific Assistant to the President, Global Research and Development. Dr. Ryser has served on numerous boards of directors in both public and private biotechnology companies. Dr. Ryser received a Ph.D. degree in molecular biology from the University of Basel.

Organization Position Status
Telik, Inc. Director and Senior Vice President, Corporate Strategy Current
Bear Stearns Asset Management Inc Managing Director Current
Raven Biotechnologies, Inc. Current
TolerRx, Inc. Board of Directors Current
Achillion Pharmaceuticals, Inc Director Current
Telik, Inc. Managing Director, Bear Stearns Health Innoventures Former
Hoffmann-La Roche Inc. Former
The Bear Stearns Companies Inc. Former
University of Basel Ph.D. Degree In Molecular Biology Former
University of Basel B.S. in biochemistry Former

Organization Position Status
Telik, Inc. Current

Organization Position Status
Telik, Inc. Member of the Board of Directors Current
Lederle Laboratories Vice President of Operations Former
Fairleigh Dickinson University M.B.A. Degree In Industrial Management Former
University of Illinois Ph.D. Degree In Organic Chemistry Former
Fairleigh Dickinson University M.B.A. Degree In Industrial Management Former

Dr. von Morze joined the Telik Board of Directors in August 2004. He is an international consultant specializing in pharmaceutical patent strategy, patent prosecution and pharmaceutical product life cycle management. Dr. von Morze most recently was Co-Chair of Heller Ehrman's Patent and Trademark Practice Group. He has directed patent prosecution and enforcement programs in the pharmaceutical industry for more than 25 years.

Organization Position Status
Telik, Inc. Board of Directors Current

Organization Position Status
D&R Products, Inc. Chief Executive Officer Current
D&R Products, Inc. President Current
Telik, Inc. Director Current
Harvard College A.B. Former
Harvard Law School Degree Former

Executive News

  • Telik Announces Presentation and Webcast at Needham Life Sciences Conference

    Pharma Live - 6/06/09 - View Story

  • Telik Announces Presentation and Webcast at Needham Life Sciences Conference

    Reuters - 6/04/09 - View Story

  • Telik Announces First Quarter 2009 Financial Results

    Pharma Live - 5/08/09 - View Story

advertisement
     TELK $0.84 -0.00 (-0.12% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 218,673
Shares Outstanding 53.43M
Market Cap 44.9M
Year High 1.4
Year Low 0.2
Earnings Per Share -0.37
P/E Ratio -2.27
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here
Presented by American Express